MedTrace Logo

Dose-ranging Study of SPL7013 Gel for the Prevention of Bacterial Vaginosis (BV)

NCT01437722 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 205

Last updated 2013-11-20

No results posted yet for this study

Summary

The purpose in this clinical study is to determine the efficacy of SPL7013 Gel for the prevention of recurrence of bacterial vaginosis.

Conditions

  • Recurrent Bacterial Vaginosis (BV)

Interventions

DRUG

1% SPL7013 Gel

vaginal gel

DRUG

3% SPL7013 Gel

vaginal gel

DRUG

placebo gel

vaginal gel

Sponsors & Collaborators

  • Starpharma Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Jeremy Paull, PhD · Starpharma Pty Ltd

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2012-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01437722 on ClinicalTrials.gov